Literature DB >> 14585389

Angiographic regression of cardiac allograft vasculopathy after introducing sirolimus immunosuppression.

Peter N Ruygrok1, Bruce Webber, Stephen Faddy, David W Muller, Anne Keogh.   

Abstract

We describe a 33-year-old heart transplant recipient who experienced several episodes of early Grade IIIA rejection and aggressive allograft vasculopathy, seen with serial coronary angiography. Two years after transplantation, we added sirolimus therapy to the patient's immunosuppressive regimen, and a further coronary angiogram 1 year later showed regression of the graft vasculopathy.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14585389     DOI： 10.1016/s1053-2498(02)01239-1

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN： 1053-2498            Impact factor:   10.247


  5 in total

Review 1.  Imaging in patients after cardiac transplantation and in patients with ventricular assist devices.

Authors:  Bhanu Gupta; Dany Jacob; Randall Thompson
Journal:  J Nucl Cardiol       Date:  2015-04-02       Impact factor: 5.952

Review 2.  Induction of vascular atrophy as a novel approach to treating restenosis. A review.

Authors:  Seung-Kee Min; Richard D Kenagy; Alexander W Clowes
Journal:  J Vasc Surg       Date:  2007-10-22       Impact factor: 4.268

3.  Low-dose rapamycin treatment increases the ability of human regulatory T cells to inhibit transplant arteriosclerosis in vivo.

Authors:  J Hester; A Schiopu; S N Nadig; K J Wood
Journal:  Am J Transplant       Date:  2012-04-14       Impact factor: 8.086

4.  Effect of imatinib mesylate and rapamycin on the preformed intimal hyperplasia in rat carotid injury model.

Authors:  Yang Jin Park; Seung-Kee Min; Sang-Il Min; Sang Joon Kim; Jongwon Ha
Journal:  Ann Surg Treat Res       Date:  2015-02-27       Impact factor: 1.859

5.  Progression of cardiac allograft vasculopathy assessed by serial three-vessel quantitative coronary angiography.

Authors:  Christian Zanchin; Kyohei Yamaji; Carolin Rogge; Dorothea Lesche; Thomas Zanchin; Yasushi Ueki; Stephan Windecker; Paul Mohacsi; Lorenz Räber; Vilborg Sigurdardottir
Journal:  PLoS One       Date:  2018-08-27       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.